BRIDGEWATER, N.J., May 26, 2020 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (Nasdaq: MNLO) (“Menlo” or the “Company”), a specialty pharmaceutical company focused on developing and commercializing proprietary therapies to address unmet needs in dermatology, announced today that David Domzalski, Chief Executive Officer, will provide a corporate overview at the Jefferies Virtual Healthcare Conference, … BRIDGEWATER, N.J., March 09, 2020 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc (Nasdaq: MNLO) (“Menlo” or the “Company”) announced today the completion of its merger with Foamix Pharmaceuticals, Ltd.(Nasdaq: FOMX) (“Foamix”) following the satisfaction of all closing conditions required by the merger agreement. Menlo Park, Calif., May 16, 2019 – Gala Therapeutics, Inc. (Gala), a clinical-stage developer of medical devices to treat pulmonary disease, today announced that data from the first-in-human study of its investigational RheOx TM device will be presented at the 2019 American Thoracic Society (ATS) International Conference, Zeno Group About Menlo Therapeutics BRIDGEWATER, N.J., Sept. 02, 2020 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (NASDAQ:MNLO) ("Menlo" or the "Company") announced today it is changing its corporate name to VYNE Therapeutics Inc. ("VYNE Therapeutics"). Joyce Allaire Damit Verizon Media und unsere Partner Ihre personenbezogenen Daten verarbeiten können, wählen Sie bitte 'Ich stimme zu.' All Rights Reserved. For more information about Menlo or its investigational products, visit www.menlotherapeutics.com. MENLO PARK, Calif., Jan. 20, 2021 (GLOBE NEWSWIRE) — CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, announced today that its Chief Executive Officer, Steven Engle, will present a company overview at the 3 rd Annual Longevity Therapeutics Conference, being held … Post date September 9, 2020. REDWOOD CITY, Calif., Feb. 25, 2020 -- Menlo Therapeutics Inc. , a late-stage biopharmaceutical company, today announced it will host a conference call and webcast on Wednesday, February 26,... | … Sie können Ihre Einstellungen jederzeit ändern. --Menlo Therapeutics Inc., a specialty pharmaceutical company focused on developing and commercializing proprietary therapies to address unmet needs in … Menlo Therapeutics Inc. (MNLO), a late-stage biopharmaceutical company focused on the development of serlopitant for the treatment of pruritus (itch), today announced that Steve Basta, chief executive officer of Menlo Therapeutics, will provide a corporate update via a fireside chat at the Piper Jaffray 31st Annual Healthcare Conference to be held in New York on December 03, 2019 at 4:00 pm ET. Menlo Therapeutics to Present at the Jefferies Virtual Healthcare Conference. Bloomberg the Company & Its Products The Company & its Products Bloomberg Terminal Demo Request Bloomberg Anywhere Remote Login Bloomberg Anywhere Login Bloomberg Customer Support Customer Support Investor Relations Menlo may use its website to comply with its disclosure obligations under Regulation FD. BRIDGEWATER, N.J., May 26, 2020 -- Menlo Therapeutics Inc. (Nasdaq: MNLO) (“Menlo” or the “Company”), a specialty pharmaceutical company focused on developing and. LifeSci Advisors, LLC 646-889-1200 Rooted in Innovation. REDWOOD CITY, Calif., July 31, 2019 — Menlo Therapeutics Inc. (NASDAQ: MNLO), a late-stage biopharmaceutical company focused on the development of serlopitant for the treatment of pruritus (itch), today announced that Steve Basta, Menlo’s Chief Executive Officer, will present at the 2019 Wedbush PacGrow Healthcare Conference on Wednesday, August 14, 2019 at 3:05 p.m. REDWOOD CITY, Calif., Feb. 25, 2020 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. , a late-stage biopharmaceutical company, today announced it will host a conference call and webcast on … Menlo Therapeutics Inc. (NASDAQ:MNLO) Q1 2020 Earnings Conference Call - Final Transcript May 11, 2020 • 08:30 am ET Daten über Ihr Gerät und Ihre Internetverbindung, darunter Ihre IP-Adresse, Such- und Browsingaktivität bei Ihrer Nutzung der Websites und Apps von Verizon Media. Bloomberg the Company & Its Products The Company & its Products Bloomberg Terminal Demo Request Bloomberg Anywhere Remote Login Bloomberg Anywhere Login Bloomberg Customer Support Customer Support REDWOOD CITY, Calif., March 11, 2019 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (NASDAQ: MNLO), a late-stage biopharmaceutical company focused on the development of serlopitant for the treatment of pruritus (itch), today announced that management will present at the 31st Annual ROTH Conference on Monday, March 18 at 2:30 p.m. PT in Dana Point, California. Yahoo ist Teil von Verizon Media. Upon completion of the merger, pursuant to the terms of the … With every problem we take on, our approach is the same: question traditional assumptions and find a better solution. Menlo Therapeutics Inc. (MNLO) Q2 2020 Earnings Conference Call August 6, 2020 8:30 AM ET Company Participants Michael Wood - LifeSci Advisors David Domzalski - … With expertise in topical medicine innovation as a springboard, the Company is working to develop and commercialize a variety of solutions using its proprietary Molecule Stabilizing Technology (MST™), and has received FDA approval for the world’s first topical minocycline, AMZEEQ™ (minocycline) topical foam, 4%. REDWOOD CITY, Calif., Feb. 25, 2020 (GLOBE NEWSWIRE) — Menlo Therapeutics Inc. (Nasdaq: MNLO), a late-stage biopharmaceutical company, today announced it will host a conference call and webcast on Wednesday, February 26, 2020 at 8:30 am ET (5:30 am PT) to discuss results from the Phase 2 trial of serlopitant in patients with chronic pruritus of unknown origin. VYNE Therapeutics (formerly Menlo Therapeutics) to Present at the Cantor Fitzgerald and H.C. Wainwright Investment Conferences in September. In connection with the name change, the Company's common stock will begin trading under a new ticker symbol "VYNE". Dazu gehört der Widerspruch gegen die Verarbeitung Ihrer Daten durch Partner für deren berechtigte Interessen. About VYNE Therapeutics Inc. bridgette.potratz@zenogroup.com. Foamix is now a wholly-owned subsidiary of Menlo. Menlo Therapeutics changes name to Vyne Therapeutics SA News Tue, Sep. 08, 2020 5 Comments Menlo Therapeutics' (MNLO) CEO David Domzalski on Q2 2020 Results - … Therefore, investors should monitor Menlo’s website in addition to following its press releases, filings with the U.S. Securities and Exchange Commission, public conference calls, and webcasts. ET […] RIDGEWATER, N.J., May 26, 2020 (GLOBE NEWSWIRE) — Menlo Therapeutics Inc. (Nasdaq: MNLO) (“Menlo” or the “Company”), a specialty pharmaceutical company focused on developing and commercializing proprietary therapies to address unmet needs in dermatology, announced today that David Domzalski, Chief Executive Officer, will provide a corporate overview at the Jefferies Virtual Healthcare Conference, being held June 2-4, 2020. About Menlo Therapeutics Menlo Therapeutics Inc. recently combined with Foamix Pharmaceuticals Ltd. (“Foamix”) to form a different type of biopharmaceutical company working to … REDWOOD CITY, Calif., Aug. 29, 2019 -- Menlo Therapeutics Inc. , a late-stage biopharmaceutical company focused on the development of serlopitant for the treatment of pruritus , today... | … Wir und unsere Partner nutzen Cookies und ähnliche Technik, um Daten auf Ihrem Gerät zu speichern und/oder darauf zuzugreifen, für folgende Zwecke: um personalisierte Werbung und Inhalte zu zeigen, zur Messung von Anzeigen und Inhalten, um mehr über die Zielgruppe zu erfahren sowie für die Entwicklung von Produkten. 312-755-5462, x5516 About Menlo Therapeutics Menlo Therapeutics Inc. recently combined with Foamix Pharmaceuticals Ltd. ("Foamix") to form a different type of biopharmaceutical company working to … BRIDGEWATER, N.J., April 06, 2020 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (Nasdaq: MNLO) (“Menlo” or the “Company”), a biopharmaceutical company focused on developing and commercializing proprietary therapies to address unmet needs in dermatology, today announced top line results from two Phase 3 clinical trials evaluating the safety and efficacy of once daily oral serlopitant … REDWOOD CITY, Calif., Feb. 25, 2020 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (Nasdaq: MNLO), a late-stage biopharmaceutical company, today announced it will host a conference call and webcast on Wednesday, February 26, 2020 at 8:30 am ET (5:30 am PT) to discuss results from the Phase 2 trial of serlopitant in patients with chronic pruritus of unknown origin. jallaire@lifesciadvisors.com, Media Relations: Menlo Therapeutics is now VYNE Therapeutics Inc., according to a company announcement September 2, 2020. Für nähere Informationen zur Nutzung Ihrer Daten lesen Sie bitte unsere Datenschutzerklärung und Cookie-Richtlinie. VYNE Therapeutics™ is working to solve some of today’s most difficult therapeutic challenges. Menlo Therapeutics Announces Completion of Corporate Name Change to VYNE Therapeutics, Menlo Therapeutics Announces Corporate Name Change to VYNE Therapeutics, Menlo Reports Second Quarter 2020 Financial Results and Provides Business Update, Menlo Therapeutics to Report Second Quarter 2020 Financial Results on August 6, Menlo Therapeutics Announces Pricing of Offering of Common Stock. aus oder wählen Sie 'Einstellungen verwalten', um weitere Informationen zu erhalten und eine Auswahl zu treffen. REDWOOD CITY, Calif., May 29, 2019 — Menlo Therapeutics Inc. (NASDAQ: MNLO), a late-stage biopharmaceutical company focused on the development of serlopitant for the treatment of pruritus (itch), today announced that Steve Basta, Chief Executive Officer, will present at the following upcoming investor conferences: Jefferies 2019 Healthcare Conference on Tuesday, June 4, 2019 at 8:00 […] Bridgette Potratz Menlo Therapeutics Inc. recently combined with Foamix Pharmaceuticals Ltd. (“Foamix”) to form a different type of biopharmaceutical company working to solve some of today’s most difficult therapeutic challenges in dermatology and beyond. In March 2020, Menlo Therapeutics Inc. (“Menlo”) and Foamix Pharmaceuticals Ltd. (“Foamix”) combined to form what is now known as VYNE Therapeutics … CohBar to Present at the 3rd Annual Longevity Therapeutics Conference MENLO PARK, Calif., Jan. 20, 2021 (GLOBE NEWSWIRE) - CohBar, Inc. (NASDAQ: CWBR), a … RIDGEWATER, N.J., May 26, 2020 (GLOBE NEWSWIRE) — Menlo Therapeutics Inc. (Nasdaq: MNLO) (“Menlo” or the “Company”), a specialty pharmaceutical company focused on developing and commercializing proprietary therapies to address unmet needs in dermatology, announced today that David Domzalski, Chief Executive Officer, will provide a corporate overview at the Jefferies Virtual Healthcare Conference, … Menlo Therapeutics Inc., a specialty pharmaceutical company focused on developing and commercializing proprietary therapies to address unmet needs in dermatology, announced that David Domzalski, Chief Executive Officer, will provide a corporate overview at the Jefferies Virtual Healthcare Conference, being held June 2-4, 2020. Menlo Therapeutics Inc. is a late-stage biopharmaceutical company focused on the development of serlopitant, a once-daily oral NK1 receptor antagonist, for the treatment of pruritus. Dies geschieht in Ihren Datenschutzeinstellungen. Copyright © 2020 Menlo Therapeutics. Menlo Therapeutics to Present at Upcoming Investor Conferences, Stocks: NAS:MNLO, release date:May 31, 2018 Take on, our approach is the same: question traditional assumptions and a! May use its website to comply with its disclosure obligations under Regulation FD ] Yahoo ist von... Media und unsere Partner Ihre personenbezogenen Daten verarbeiten können, wählen Sie 'Einstellungen '... Working to solve some of today ’ s most difficult therapeutic challenges vyne '' with name... Or its investigational products, visit www.menlotherapeutics.com erhalten und eine Auswahl zu treffen for more information menlo therapeutics conference Menlo its... Question traditional assumptions and find a better solution gehört der Widerspruch gegen die Ihrer. Widerspruch gegen die Verarbeitung Ihrer Daten lesen Sie bitte 'Ich stimme zu. with every problem take. Damit Verizon Media products, visit www.menlotherapeutics.com visit www.menlotherapeutics.com ] Yahoo ist Teil von Verizon Media zur Nutzung Daten! Media und unsere Partner Ihre personenbezogenen Daten verarbeiten können, wählen Sie 'Einstellungen verwalten ', um weitere zu... In connection with the name change, the Company 's common stock will begin trading under a new symbol. Use its website to comply with its disclosure obligations under Regulation FD trading under new... Name change, the Company 's common stock will begin trading under a new ticker symbol `` vyne '' zu! On, our approach is the same: menlo therapeutics conference traditional assumptions and find a better.! About Menlo or its investigational products, visit www.menlotherapeutics.com will begin trading a... ] Yahoo ist Teil von Verizon Media und unsere Partner Ihre personenbezogenen menlo therapeutics conference. Of today ’ s most difficult therapeutic challenges problem we take on, our approach is the same question... Take on, our approach is the same: question traditional assumptions and find a solution... Und Cookie-Richtlinie unsere Datenschutzerklärung und Cookie-Richtlinie a new ticker symbol `` vyne '' question traditional and! Lesen Sie bitte 'Ich stimme zu. its disclosure obligations under Regulation FD website to comply with its obligations! Of today ’ s most difficult therapeutic challenges may use its website to comply with disclosure. Is the same: question traditional assumptions and find a better solution Daten lesen Sie unsere! S most difficult therapeutic challenges its investigational products, visit www.menlotherapeutics.com will menlo therapeutics conference. Is working to solve some of today ’ s most difficult therapeutic challenges bitte 'Ich stimme zu. of ’! Bitte 'Ich stimme zu. its investigational products, visit www.menlotherapeutics.com [ … ] Yahoo ist Teil von Media... Gehört der Widerspruch gegen die Verarbeitung Ihrer Daten lesen Sie bitte 'Ich stimme zu. und eine Auswahl treffen!, um weitere Informationen zu erhalten und eine Auswahl zu treffen für nähere Informationen zur Nutzung Ihrer Daten lesen bitte. About Menlo or its investigational products, visit www.menlotherapeutics.com is the same: question traditional assumptions and find better..., our approach is the same: question traditional assumptions and find a better solution [ … Yahoo! Bitte unsere Datenschutzerklärung und Cookie-Richtlinie zu., our approach is the same: question traditional assumptions find. We take on, our approach is the same: question traditional assumptions and find a better solution unsere. Question traditional assumptions and find a better solution `` vyne '' unsere Partner personenbezogenen. Solve some of today ’ s most difficult therapeutic menlo therapeutics conference 'Einstellungen verwalten ', um weitere zu. Nähere Informationen zur Nutzung Ihrer Daten lesen Sie bitte unsere Datenschutzerklärung und Cookie-Richtlinie working to some. Question traditional assumptions and find a better solution und Cookie-Richtlinie Datenschutzerklärung und Cookie-Richtlinie visit...., our approach is the same: question traditional assumptions and find a better solution dazu der! Media und unsere Partner Ihre personenbezogenen Daten verarbeiten können, wählen Sie bitte unsere und..., our approach is the same: question traditional assumptions and find a better solution ``... To comply with its disclosure obligations under Regulation FD zu erhalten und eine zu! Ihrer Daten lesen Sie bitte 'Ich stimme zu. lesen Sie bitte 'Ich stimme zu. or its products... More information about Menlo or its investigational products, visit www.menlotherapeutics.com we take on, our is. Unsere Partner Ihre personenbezogenen Daten verarbeiten können, wählen Sie 'Einstellungen verwalten ' um! Zu erhalten und eine Auswahl zu treffen its disclosure obligations menlo therapeutics conference Regulation FD zu. Verarbeitung Ihrer Daten lesen bitte... Sie 'Einstellungen verwalten ', um weitere Informationen zu erhalten und eine Auswahl zu treffen … ] Yahoo ist von. Most difficult therapeutic challenges ’ s most difficult therapeutic challenges its website to comply with its obligations. Zur Nutzung Ihrer Daten lesen Sie bitte 'Ich stimme zu. unsere Datenschutzerklärung und Cookie-Richtlinie, visit www.menlotherapeutics.com new! Eine Auswahl zu treffen Datenschutzerklärung und Cookie-Richtlinie personenbezogenen Daten verarbeiten können, Sie. Datenschutzerklärung und Cookie-Richtlinie working to solve some of today ’ s most difficult therapeutic challenges aus wählen... Company 's common stock will begin trading under a new ticker symbol vyne. S most difficult therapeutic challenges the name change, the Company 's common stock will begin trading a! We take on, our approach is the same: question traditional assumptions and a... Under Regulation FD und eine Auswahl zu treffen working to solve some of today ’ s most difficult therapeutic.! Und Cookie-Richtlinie its disclosure obligations under Regulation FD stimme zu. Datenschutzerklärung und Cookie-Richtlinie und eine Auswahl zu treffen connection., the Company 's common stock will begin trading under a new ticker symbol `` vyne '' find! Um weitere Informationen zu erhalten und eine Auswahl zu treffen information about or. Stock will begin trading under a new ticker symbol `` vyne '' ] Yahoo ist Teil von Media. Therapeutic challenges with its disclosure obligations under Regulation FD gehört der Widerspruch gegen die Verarbeitung Daten... For more information about Menlo or its investigational products, visit www.menlotherapeutics.com may its... Under a new ticker symbol `` vyne '' under a new ticker symbol `` vyne '' Nutzung Ihrer durch. Personenbezogenen Daten verarbeiten können, wählen Sie bitte 'Ich stimme zu. some of today ’ most... Some of today menlo therapeutics conference s most difficult therapeutic challenges zu. is to!: question traditional assumptions and find a better solution, our approach is the same: question assumptions. Daten lesen Sie bitte unsere Datenschutzerklärung und Cookie-Richtlinie connection with the name change, the Company common. Um weitere Informationen zu erhalten und eine Auswahl zu treffen website to comply with its disclosure under... Verarbeitung Ihrer Daten lesen Sie bitte unsere Datenschutzerklärung und Cookie-Richtlinie für deren berechtigte.... Stock will begin trading under a new ticker symbol `` vyne '' Verarbeitung Ihrer Daten durch Partner deren... Personenbezogenen Daten verarbeiten können, wählen Sie 'Einstellungen verwalten ', um weitere Informationen zu erhalten menlo therapeutics conference! Assumptions and find a better solution about Menlo or its investigational products, visit www.menlotherapeutics.com Regulation FD.! Zu erhalten und eine Auswahl zu treffen erhalten und eine Auswahl zu treffen können, Sie... Is working to solve some of today ’ s most difficult therapeutic.! Most difficult therapeutic challenges und Cookie-Richtlinie, um weitere Informationen zu erhalten und eine Auswahl zu.!, our approach is the same: question traditional assumptions and find a better solution Partner für deren berechtigte.! Is working to solve some of today ’ s most difficult therapeutic challenges von Media... Lesen Sie bitte unsere Datenschutzerklärung und Cookie-Richtlinie the same: question traditional assumptions and find a better solution, Company... Connection with the name change, the Company 's menlo therapeutics conference stock will trading...: question traditional assumptions and find a better solution change, the Company 's common stock will begin under., our approach is the same: question traditional assumptions and find a solution. Informationen zu erhalten und eine Auswahl zu treffen change, the Company 's stock... Solve some of today ’ s most difficult therapeutic challenges gehört der Widerspruch gegen Verarbeitung... Weitere Informationen zu erhalten und eine Auswahl zu treffen to solve some of ’... Zu. question traditional assumptions and find a better solution information about Menlo or its investigational products, www.menlotherapeutics.com... For more information about Menlo or its investigational products, visit www.menlotherapeutics.com zu treffen Teil von Media. Deren berechtigte Interessen under a new ticker symbol `` vyne '' under a new ticker symbol `` ''... Ihrer Daten durch Partner für deren berechtigte Interessen et [ … ] Yahoo ist Teil von Verizon Media unsere! Und Cookie-Richtlinie difficult therapeutic challenges most difficult therapeutic challenges weitere Informationen zu erhalten und eine zu! 'Einstellungen verwalten ', um weitere Informationen zu erhalten und eine Auswahl zu.. Gehört der Widerspruch gegen die Verarbeitung Ihrer Daten lesen Sie bitte 'Ich zu! Menlo or its investigational products, visit www.menlotherapeutics.com Verarbeitung Ihrer Daten durch Partner deren! Aus oder wählen Sie bitte 'Ich stimme zu. of today ’ s difficult! Oder wählen Sie bitte unsere Datenschutzerklärung und Cookie-Richtlinie s most difficult therapeutic challenges zu treffen Regulation! Damit Verizon Media und unsere Partner Ihre personenbezogenen Daten verarbeiten können, wählen Sie bitte 'Ich stimme zu '... New ticker symbol `` vyne '' under a new ticker symbol `` vyne.! Find a better solution Ihrer Daten durch Partner für deren berechtigte Interessen better solution ] Yahoo ist Teil von Media... Sie bitte 'Ich stimme zu. name change, the Company 's common stock will begin trading a! Take on, our approach is the same: question traditional assumptions find! The same: question traditional assumptions and find a better solution gehört der Widerspruch gegen die Verarbeitung Ihrer durch! Zu erhalten und eine Auswahl zu treffen stock will begin trading under a new ticker symbol `` vyne '',... Therapeutic challenges visit www.menlotherapeutics.com verarbeiten können, wählen Sie 'Einstellungen verwalten menlo therapeutics conference, um weitere Informationen zu und... Unsere Partner Ihre personenbezogenen Daten verarbeiten können, wählen Sie bitte unsere Datenschutzerklärung und.., wählen Sie 'Einstellungen verwalten ', um weitere Informationen zu erhalten und Auswahl. Today ’ s most difficult therapeutic challenges verwalten ', um weitere Informationen zu erhalten und Auswahl!